BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Paratek Pharmaceuticals, Inc. 

75 Kneeland Street

Boston  Massachusetts  02111  U.S.A.
Phone: 617-275-0040 Fax: 617-275-0039


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Paratek Pharmaceuticals, Inc. is a private biopharmaceuticals company engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases. Paratek has a particular focus on developing new therapeutics for the infectious disease market to combat the problem of antibiotic resistance. Paratek was founded in 1996 by Dr. Stuart B. Levy, the world-renowned expert in antibiotic resistance and Professor of Molecular Biology and Microbiology and of Medicine at Tufts University School of Medicine, and by Dr. Walter Gilbert, the successful biotechnology entrepreneur and well-known Nobel Prize-winning Professor at Harvard University. Paratek was created to harness the 30+ years of research and discovery in mechanisms of antibiotic resistance and tetracycline chemistry by Dr. Levy and his scientific team at Tufts University School of Medicine.

Paratek has established two product development programs to identify and develop multiple products for the treatment of infectious diseases:

  • The Tetracycline Resistance Project (Tet Project), based on expertise in medicinal chemistry
  • The Multiple Antibiotic Resistance Project (Mar Project), based on novel discoveries in pathogen genomics

Senior Management:
Thomas J. Bigger, President & Chief Executive Officer
Stuart B. Levy, M.D., Chief Scientific Officer
Beverly A. Armstrong, Vice President & Chief Financial Officer
George C. Hillman, Executive Vice President & Chief Operating Officer
S. Ken Tanaka, Vice President of Research & Development
Dennis Molnar, Executive Director of Corporate Development

Board of Directors
Walter Gilbert, Ph.D., Chairman
Stuart B. Levy, M.D., Vice Chairman & CSO
Thomas J. Bigger, President & CEO, Director
Kalevi Kurkijarvi, Ph.D., Director
Kenneth J. Novack, Director
Sir Mark Richmond, Ph.D., Director
Patricia Smith, M.D., Director
Pieter Strijkert, Ph.D., Director

Last Updated: 04-23-02


 Key Statistics


Email: ir@paratekpharm.com
Ownership: Private

Web Site: Paratek Pharmaceuticals, Inc.
Employees: 76
Symbol: 
 









 Company News
Paratek Pharmaceuticals, Inc. Announces Appointment Of Douglas Pagan As Chief Financial Officer 12/5/2014 8:58:50 AM
Paratek Pharmaceuticals, Inc. Highlights Newly Expanded Board Of Directors 11/6/2014 1:03:11 PM
Paratek Pharmaceuticals, Inc. Strengthens Management Team 11/4/2014 7:22:11 AM
Paratek Pharmaceuticals, Inc. Completes Merger With Transcept Pharmaceuticals, Inc. (TSPT) 10/31/2014 7:27:52 AM
Transcept Pharmaceuticals, Inc. (TSPT) Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals, Inc. 10/15/2014 8:00:51 AM
Paratek Pharmaceuticals, Inc. Taps A New CEO 7/1/2014 10:12:46 AM
Bay Area's Transcept Pharmaceuticals, Inc. (TSPT) Soars On Plans To Merge With Paratek Pharmaceuticals, Inc., Picks Up $93 Million Along The Way; Transcept Stock Up +19.60% At Market Close (July 1, 2014) 7/1/2014 6:24:15 AM
Paratek Pharmaceuticals, Inc. Announces FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline 1/4/2013 8:55:03 AM
Paratek Pharmaceuticals, Inc. Files for a $92 Million IPO 9/28/2012 6:33:43 AM
Paratek Pharmaceuticals, Inc. Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors 5/22/2012 7:06:53 AM
1234